HEALTHJun 8 · 20:15 UTCSTAT NEWSElaine Chen

STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca's investigational GLP-1 pill, elecoglipron, demonstrated significant weight loss in a Phase 2 obesity trial (11.2% after 36 weeks) and improved blood sugar control in a diabetes trial (1.74 percentage-point A1C reduction). Results were compared to oral Ozempic, which showed a smaller A1C decrease in the same study.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

AstraZenecaorganizationelecogliprontopicVISTAtopicSOLSTICEtopicobesitytopicdiabetestopicOzempictopicAmerican Diabetes AssociationorganizationLancetorganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 14 · 11:00 UTC
Experimental obesity drug outperforms traditional weight-loss treatments in early research
HEALTHJun 7 · 13:28 UTC
The promises and pitfalls of GLP-1 drugs
HEALTHMay 21 · 16:50 UTC
New weight-loss shot appears to outperform other obesity drugs on market
HEALTHMay 7 · 10:37 UTC
New “Trojan horse” obesity drug supercharges weight loss in early tests
HEALTHMay 21 · 23:51 UTC
New weight-loss drug Retatrutide showing stronger results than current options